[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals Inc (ACXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,747
  • Shares Outstanding, K 4,298
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,970 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta -2.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.42
  • Number of Estimates 1
  • High Estimate $-0.42
  • Low Estimate $-0.42
  • Prior Year $-1.89
  • Growth Rate Est. (year over year) +77.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5100 +1.99%
on 06/16/26
2.2200 -30.63%
on 05/22/26
-0.3800 (-19.79%)
since 05/15/26
3-Month
1.5100 +1.99%
on 06/16/26
7.5392 -79.57%
on 03/19/26
-3.2700 (-67.98%)
since 03/16/26
52-Week
1.3259 +16.15%
on 03/06/26
21.0000 -92.67%
on 06/17/25
-4.6020 (-74.93%)
since 06/16/25

Most Recent Stories

More News
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

STATEN ISLAND, N.Y. , June 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small...

ACXP : 1.5400 (-1.91%)
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / New to The Street's longtime featured biotechnology client, Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), highlighted a potentially transformative regulatory...

ACXP : 1.5400 (-1.91%)
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity

ACXP : 1.5400 (-1.91%)
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

STATEN ISLAND, N.Y. , April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics...

ACXP : 1.5400 (-1.91%)
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit

Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class...

ACXP : 1.5400 (-1.91%)
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

STATEN ISLAND, N.Y. , April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 1.5400 (-1.91%)
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics

The show also broadcasts as sponsored programming additionally across MENA and Latin America as "Nuevo En La Calle," reaching millions of households worldwide weekly, with expanded digital distribution...

CAST : 3.75 (unch)
NTHI : 5.18 (+14.86%)
ACXP : 1.5400 (-1.91%)
IGC : 0.2776 (-1.00%)
VTIX : 3.39 (-0.29%)
MDCX : 0.3349 (+4.66%)
YYGH : 0.1410 (+11.73%)
DVLT : 0.3864 (-1.68%)
VVOS : 0.5445 (-5.68%)
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

ACXP : 1.5400 (-1.91%)
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

ACXP : 1.5400 (-1.91%)
New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Media Campaigns and Accredited Investor Events

Three Consecutive Years of Ongoing Predictable Mediaâ„¢ Partnership

ACXP : 1.5400 (-1.91%)

Business Summary

Acurx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It focused on developing new antibiotics to treat infections. Acurx Pharmaceuticals Inc. is based in STATEN ISLAND, N.Y.

See More

Key Turning Points

3rd Resistance Point 1.7133
2nd Resistance Point 1.6667
1st Resistance Point 1.6033
Last Price 1.5400
1st Support Level 1.4933
2nd Support Level 1.4467
3rd Support Level 1.3833

See More

52-Week High 21.0000
Fibonacci 61.8% 13.4845
Fibonacci 50% 11.1629
Fibonacci 38.2% 8.8414
Last Price 1.5400
52-Week Low 1.3259

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.